Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month High – What’s Next?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shares reached a new 52-week high during trading on Monday . The stock traded as high as $62.64 and last traded at $59.71, with a volume of 5611537 shares. The stock had previously closed at $41.94.

Analyst Upgrades and Downgrades

XENE has been the topic of several recent research reports. Wolfe Research assumed coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price target on the stock. Wells Fargo & Company upped their price target on Xenon Pharmaceuticals from $48.00 to $49.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Needham & Company LLC lifted their price objective on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Jefferies Financial Group reissued a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $55.50.

Xenon Pharmaceuticals Price Performance

The stock’s 50 day simple moving average is $42.25 and its two-hundred day simple moving average is $41.24. The firm has a market cap of $5.10 billion, a P/E ratio of -14.06 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the previous year, the company earned ($0.84) earnings per share. Equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at $266,580. The trade was a 86.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.07% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Elevation Point Wealth Partners LLC bought a new position in shares of Xenon Pharmaceuticals in the second quarter worth approximately $32,000. Danske Bank A S purchased a new position in Xenon Pharmaceuticals in the 3rd quarter worth approximately $32,000. Blue Trust Inc. raised its holdings in Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Xenon Pharmaceuticals in the 4th quarter valued at approximately $33,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at $39,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.